JP2017535246A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535246A5
JP2017535246A5 JP2017512808A JP2017512808A JP2017535246A5 JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5 JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535246A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048659 external-priority patent/WO2016037119A1/en
Publication of JP2017535246A publication Critical patent/JP2017535246A/ja
Publication of JP2017535246A5 publication Critical patent/JP2017535246A5/ja
Pending legal-status Critical Current

Links

JP2017512808A 2014-09-05 2015-09-04 新規の抗mfi2抗体および使用方法 Pending JP2017535246A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462046610P 2014-09-05 2014-09-05
US62/046,610 2014-09-05
US201562203836P 2015-08-11 2015-08-11
US62/203,836 2015-08-11
PCT/US2015/048659 WO2016037119A1 (en) 2014-09-05 2015-09-04 Novel anti-mfi2 antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2017535246A JP2017535246A (ja) 2017-11-30
JP2017535246A5 true JP2017535246A5 (cg-RX-API-DMAC7.html) 2019-04-25

Family

ID=55440418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512808A Pending JP2017535246A (ja) 2014-09-05 2015-09-04 新規の抗mfi2抗体および使用方法

Country Status (22)

Country Link
US (1) US10428156B2 (cg-RX-API-DMAC7.html)
EP (1) EP3189079A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017535246A (cg-RX-API-DMAC7.html)
KR (1) KR20170045351A (cg-RX-API-DMAC7.html)
CN (1) CN107001454A (cg-RX-API-DMAC7.html)
AU (1) AU2015311743A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017004444A2 (cg-RX-API-DMAC7.html)
CA (1) CA2959705A1 (cg-RX-API-DMAC7.html)
CL (2) CL2017000506A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017003005A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170117A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000052A (cg-RX-API-DMAC7.html)
EA (1) EA201790529A1 (cg-RX-API-DMAC7.html)
IL (1) IL250825A0 (cg-RX-API-DMAC7.html)
MA (1) MA40612A (cg-RX-API-DMAC7.html)
MX (1) MX2017002862A (cg-RX-API-DMAC7.html)
PE (1) PE20170776A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500406A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701650PA (cg-RX-API-DMAC7.html)
TW (1) TW201617368A (cg-RX-API-DMAC7.html)
WO (1) WO2016037119A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701674B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190353A1 (es) 2016-04-15 2019-03-07 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
JPWO2019167874A1 (ja) * 2018-02-27 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Apoa4に対するモノクローナル抗体、免疫学的測定方法及び測定用キット
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
US12134650B2 (en) * 2018-07-26 2024-11-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer
EP3897739B1 (en) * 2018-12-21 2024-04-17 Sapreme Technologies B.V. Saponin conjugates
CN109709340B (zh) * 2018-12-29 2022-02-11 江苏众红生物工程创药研究院有限公司 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
CN113710271B (zh) * 2019-02-05 2025-03-04 西根股份有限公司 抗cd228抗体和抗体-药物缀合物
CA3147044A1 (en) 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
GB201913594D0 (en) * 2019-09-20 2019-11-06 Univ Birmingham Epigenetic profiling method
CN111909933B (zh) * 2020-06-29 2021-07-02 浙江大学 靶向细胞表面抗原mfi2蛋白的核酸适配体及应用
KR20230042518A (ko) * 2020-08-04 2023-03-28 씨젠 인크. 항-cd228 항체 및 항체-약물 컨쥬게이트
WO2022187050A1 (en) * 2021-03-01 2022-09-09 BioLegend, Inc. Anti-cd117 agents and compositions and methods for making and using the same
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
WO2024064714A2 (en) * 2022-09-21 2024-03-28 Seagen Inc. Antibodies that bind cd228
WO2025025731A1 (zh) * 2023-07-28 2025-02-06 山东博安生物技术股份有限公司 一种适用于免疫组化检测cd228的诊断抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5191066A (en) 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1997035589A1 (en) 1996-03-26 1997-10-02 Kopreski Michael S Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
WO1999037779A1 (en) 1998-01-22 1999-07-29 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
WO2000012508A2 (en) 1998-08-27 2000-03-09 Spirogen Limited Pyrrolbenzodiazepines
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
WO2001059459A2 (en) 2000-02-08 2001-08-16 University Of British Columbia Compositions and methods for screening therapeutic agents
KR20020007432A (ko) 2000-07-13 2002-01-29 박현석 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
EP1256354A1 (en) 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
EP1419786A1 (en) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP1626735B1 (en) * 2003-05-09 2014-11-19 Transfert Plus Compound for treating cancer caused by cells expressing melanotransferrin at their surface
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
PT1720881E (pt) 2004-03-01 2013-02-04 Spirogen Sarl Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
EP1725586B1 (en) 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
ATE527262T1 (de) 2006-01-25 2011-10-15 Sanofi Sa Neue tomaymycin derivate enhaltende zytotoxische mittel
NZ597251A (en) 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
CN101501187A (zh) 2006-06-06 2009-08-05 田纳西大学研究基金会 富含赘生干细胞的组合物及包含其的方法
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
CA3153438C (en) 2006-09-07 2024-03-12 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8309354B2 (en) 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Igf―1r의 다중 에피토프에 결합하는 조성물
EP4512422A3 (en) 2007-09-14 2025-05-21 Amgen Inc. Homogenous antibody populations
US20090155255A1 (en) 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
CN102083460A (zh) 2008-01-18 2011-06-01 米迪缪尼有限公司 用于位点特异性偶联的半胱氨酸工程化抗体
WO2010037134A2 (en) 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
KR101776976B1 (ko) 2010-02-21 2017-09-08 바이엘 헬스케어 엘엘씨 생체분자의 활성화 및 접합 방법
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
EP2558475A1 (en) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazepines used to treat proliferative diseases
CN103068405A (zh) * 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
RS52983B (sr) 2010-04-15 2014-02-28 Spirogen Sárl Pirolobenzodiazepini i njihovi konjugati
CN119552249A (zh) 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
AU2011295722B2 (en) 2010-09-03 2016-04-21 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
EP3444267B1 (en) 2010-09-17 2020-09-09 National Institute of Advanced Industrial Science and Technology Lung cancer differential marker
JP6014596B2 (ja) 2010-11-09 2016-10-25 メディミューン,エルエルシー 均一コンジュゲーションのための抗体足場
WO2012078761A2 (en) 2010-12-09 2012-06-14 Bayer Healthcare Llc Dimeric molecular complexes with free cysteine residues and conjugates thereof
RS56793B1 (sr) 2011-03-02 2018-04-30 Roche Glycart Ag Cea antitela
BR112014002219A2 (pt) * 2011-07-05 2018-08-07 Bioasis Technologies Inc conjugados anticorpo p97 e métodos de sua utilização
ES2654111T3 (es) 2011-08-05 2018-02-12 Bioasis Technologies Inc. Fragmentos p97 con actividad de transferencia
JP2014530825A (ja) 2011-10-19 2014-11-20 セラテクノロジーズ・インコーポレーテッド メラノトランスフェリン由来のペプチド化合物及びその使用
KR20110136776A (ko) * 2011-12-12 2011-12-21 경북대학교 산학협력단 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법
ES2816078T3 (es) 2011-12-20 2021-03-31 Medimmune Llc Polipéptidos modificados para armazones de anticuerpo biespecífico
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
SG10201801444WA (en) * 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
BR112014022228A2 (pt) 2012-03-08 2017-07-11 Halozyme Inc anticorpos anti-epidérmicos de receptor de fator de crescimento condicionalmente ativo e métodos de uso dos mesmos
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
JP6109937B2 (ja) * 2012-07-20 2017-04-05 クリーブ バイオサイエンシズ インコーポレイテッド p97複合体の阻害剤としての融合ピリミジン
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
PT3470086T (pt) 2012-10-12 2021-02-01 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
AU2014214751B2 (en) 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
ES2774549T3 (es) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragmentos de P97 y usos de los mismos
KR20160018579A (ko) 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
KR20210115051A (ko) 2013-06-10 2021-09-24 다나-파버 캔서 인스티튜트 인크. 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
WO2015123265A1 (en) 2014-02-11 2015-08-20 Seattle Genetics, Inc. Selective reduction of proteins
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
WO2016064749A2 (en) 2014-10-20 2016-04-28 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use

Similar Documents

Publication Publication Date Title
JP2017535246A5 (cg-RX-API-DMAC7.html)
US9353182B2 (en) Anti-DLL3 antibodies
ES2763548T3 (es) Anticuerpos anti-TIM3 y procedimientos de uso
JP2016531915A5 (cg-RX-API-DMAC7.html)
JP2018127469A5 (cg-RX-API-DMAC7.html)
JP2016531914A5 (cg-RX-API-DMAC7.html)
JP2019532056A5 (cg-RX-API-DMAC7.html)
KR20160070191A (ko) 신규한 항-클라우딘 항체 및 사용 방법
JP2018529656A (ja) 抗dll3抗体薬物コンジュゲートおよび使用方法
KR20160097336A (ko) 신규 항-dpep3 항체 및 이의 사용 방법
JP2016536020A5 (cg-RX-API-DMAC7.html)
CN110494448B (zh) 包含抗-ly75抗体的医药组合
US20190201542A1 (en) Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition
KR20160047567A (ko) 조작된 항-dll3 접합체 및 사용 방법
JP7657213B2 (ja) 抗メソテリンエリブリン抗体-薬物コンジュゲート及び使用方法
KR20180088445A (ko) 신규한 항-클라우딘 항체 및 사용 방법
JP2015509948A5 (cg-RX-API-DMAC7.html)
ES3007557T3 (en) Anti-edb antibodies and antibody-drug conjugates
JP2020502271A (ja) 抗cubドメイン含有タンパク質1(cdcp1)抗体、抗体薬物コンジュゲート、およびその使用方法
KR20170045351A (ko) 신규한 항-mfi2 항체 및 사용 방법
JP7578289B2 (ja) Muc18に特異的な抗体
AU2016355206A1 (en) Novel anti-EMR2 antibodies and methods of use
JP2019511199A (ja) 新規の抗upk1b抗体及び使用方法
AU2017261369A1 (en) Novel anti-TNFRSF21 antibodies and methods of use
JPWO2020143749A5 (cg-RX-API-DMAC7.html)